Splenic size as a marker for active inflammation in Crohn's disease

Khashper, Alla; Shwartz, Doron; Taragin, Benjamin H.; Shalmon, Tamar

doi:10.1016/j.clinimag.2022.02.012

Cited by 7 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 An enlarged spleen is an indicator of active inflammation in IBD patients due to its role in autoimmune response. 16 In the current study, all mice that received DSS water had a significantly higher spleen to body weight ratio than the healthy group (Fig. 2B).…”

Section: Papersupporting

confidence: 48%

Dealcoholized muscadine wine was partially effective in preventing and treating dextran sulfate sodium-induced colitis and restoring gut dysbiosis in mice

Li¹,

Christman²,

Yağız³

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

Section: Papersupporting

confidence: 48%

Dealcoholized muscadine wine was partially effective in preventing and treating dextran sulfate sodium-induced colitis and restoring gut dysbiosis in mice

Li¹,

Christman²,

Yağız³

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

“…Splenic volume is known to enlarge in CD patients compared to a healthy population, especially in the active stage ( Kawashima et al, 2022 ; Khashper et al, 2022 ). Few studies focus on the influence of IFX treatment on splenic volume in CD.…”

Section: Discussionmentioning

confidence: 99%

“… Harris et al (2010) verified that splenic volume was negatively correlated with age and positively correlated with body weight, BMI, and body surface area (BSA). In previous studies, splenic volume was adjusted by dividing by either body weight or BMI ( Kawashima et al, 2022 ; Khashper et al, 2022 ). In our study, although splenic volume, SV/BMI, and SV/W all showed significant differences before and after IFX treatment in both groups, SV/BMI provided the strongest significance among these indicators as its p -value was the smallest (SV p = 0.00057, SV/BMI p = 9.11E-07, and SV/W p = 1.00E-06 in the response group), which suggested that SV/BMI may be a better indicator ( Table.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies also reported splenomegaly in CD ( Rozen et al, 1977 ; Palmer et al, 1981 ; Pereira et al, 1987 ). Additionally, Khashper et al (2022) and Kawashima et al (2022) discovered that splenic volume and spleen volume adjusted for body weight were significantly increased in CD patients compared to the healthy population through a retrospective study. Moreover, both splenic volume adjusted for body mass index (BMI) and splenic volume adjusted for body weight, rather than splenic volume only, were positively correlated with disease activity ( Kawashima et al, 2022 ; Khashper et al, 2022 ), considering that splenic volume was positively affected by BMI and body weight ( Harris et al, 2010 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab

Shi,

Wang,

Rao

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Background: A number of patients with Crohn’s disease (CD) suffer from loss of response to infliximab (IFX) therapy. Splenic volume is reported to be enlarged in patients with CD compared to normal individuals. The association between splenic volume and IFX efficacy in CD remains unclear.Methods: We performed a retrospective study of patients with CD who received regular IFX treatment at Zhongshan Hospital, Fudan University, between August 2015 and December 2021. We collected baseline characteristics and clinical features from medical records in the CD database of Zhongshan Hospital. We accurately measured the splenic volume using semi-auto spleen segmentation software, followed by the analysis of splenic volume and IFX efficacy.Results: We included 49 patients with CD receiving IFX treatment, of whom 41 responded to IFX and 8 failed to respond to IFX. Splenic volume, as well as volume adjusted for body mass index (SV/BMI) and body weight (SV/W), was significantly decreased after IFX treatment in responders but increased in non-responders compared to the volume before the treatment. Accordingly, the levels of leukocyte count, platelet count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were decreased after IFX treatment in responders. Contrarily, the levels of hemoglobin, albumin, and tumor necrosis factor (TNF)-α were elevated in responders. Moreover, both CRP and TNF-α levels were significantly positively correlated with SV/BMI in all patients.Conclusion: Splenic volume, especially SV/BMI and SV/W, was reduced after IFX treatment in CD patients responsive to IFX. SV/BMI was positively correlated with disease activity. Splenic volume is a promising indicator to evaluate IFX efficacy in CD.

show abstract

Utility of spleen volume to body mass index ratio in Crohn’s disease—A retrospective cohort study

Azam,

Senthamizhselvan,

Mohan

et al. 2024

Indian J Gastroenterol

View full text Add to dashboard Cite

Splenic size as a marker for active inflammation in Crohn's disease

Cited by 7 publications

References 17 publications

Dealcoholized muscadine wine was partially effective in preventing and treating dextran sulfate sodium-induced colitis and restoring gut dysbiosis in mice

Dealcoholized muscadine wine was partially effective in preventing and treating dextran sulfate sodium-induced colitis and restoring gut dysbiosis in mice

A novel role of the splenic volume in Crohn’s disease: evaluating the efficacy of infliximab

Utility of spleen volume to body mass index ratio in Crohn’s disease—A retrospective cohort study

Contact Info

Product

Resources

About